Literature DB >> 7126412

The minimum effective analgetic blood concentration of pethidine in patients with intractable pain.

L E Mather, C J Glynn.   

Abstract

1 Pethidine infusions were performed in 16 patients with intractable pain in order to define a minimum effective analgetic blood concentration (MEAC) range. 2 Pethidine blood concentrations at the return of pain following a period of analgesia were considered to provide a more useful estimation of the MEAC than that at the onset of analgesia. 3. The MEAC range found in 15 of the 16 patients was 0.10 mg/l to 0.82 mg/l (median 0.25 mg/l). The intravenous dose of pethidine used in this study did not provide analgesia in one patient. 4 If the MEAC was greater than 0.40 mg/l in any patient, then additional techniques were required to provide adequate long term analgesia, e.g. destructive neurolytic techniques or antidepressant therapy. 5 The pharmacokinetic properties of pethidine found in the majority of these patients were in the range considered to be normal. 6 The clinical pharmacokinetic properties of pethidine found in the majority of these patients were in the range considered to be normal. 6 The clinical pharmacokineticist has in important role to play in the investigation, diagnosis and treatment of patients with intractable pain by detecting those patients with atypical pharmacokinetic and/or pharmacodynamic characteristics towards analgesic drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7126412      PMCID: PMC1427627          DOI: 10.1111/j.1365-2125.1982.tb01995.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Relief of pain in incurable cancer.

Authors:  R M MAHER
Journal:  Lancet       Date:  1955-01-01       Impact factor: 79.321

2.  Fentanyl disposition in cerebrospinal fluid and plasma and its relationship to ventilatory depression in the dog.

Authors:  C C Hug; M R Murphy
Journal:  Anesthesiology       Date:  1979-04       Impact factor: 7.892

3.  A pharmacokinetic approach to postoperative pain: continuous infusion of pethidine.

Authors:  J V Stapleton; K L Austin; L E Mather
Journal:  Anaesth Intensive Care       Date:  1979-02       Impact factor: 1.669

4.  Meperidine and other basic drugs: general method for their determination in plasma.

Authors:  L E Mather; G T Tucker
Journal:  J Pharm Sci       Date:  1974-02       Impact factor: 3.534

5.  Rate of formation of norpethidine from pethidine.

Authors:  K L Austin; J V Stapleton; L E Mather
Journal:  Br J Anaesth       Date:  1981-03       Impact factor: 9.166

6.  The clinical assessment of analgesic drugs.

Authors:  D W Littlejohns; D W Vere
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

7.  Pharmacokinetics of morphine injected intravenously into the anesthetized dog.

Authors:  C C Hug; M R Murphy; E P Rigel; W A Olson
Journal:  Anesthesiology       Date:  1981-01       Impact factor: 7.892

8.  Relationship between blood meperidine concentrations and analgesic response: a preliminary report.

Authors:  K L Austin; J V Stapleton; L E Mather
Journal:  Anesthesiology       Date:  1980-12       Impact factor: 7.892

Review 9.  Clinical pharmacokinetics of pethidine.

Authors:  L E Mather; P J Meffin
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

10.  Pethidine clearance during continuous intravenous infusions in postoperative patients.

Authors:  K L Austin; J V Stapleton; L E Mather
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

  10 in total
  4 in total

Review 1.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

Review 2.  Obstetric analgesia. Clinical pharmacokinetic considerations.

Authors:  J Kanto
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

Review 3.  Newer methods of delivery of opiates for relief of pain.

Authors:  P J Slattery; R A Boas
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

4.  Expansion of the human mu-opioid receptor gene architecture: novel functional variants.

Authors:  Svetlana A Shabalina; Dmitri V Zaykin; Pavel Gris; Aleksey Y Ogurtsov; Josee Gauthier; Kyoko Shibata; Inna E Tchivileva; Inna Belfer; Bikashkumar Mishra; Carly Kiselycznyk; Margaret R Wallace; Roland Staud; Nikolay A Spiridonov; Mitchell B Max; David Goldman; Roger B Fillingim; William Maixner; Luda Diatchenko
Journal:  Hum Mol Genet       Date:  2008-12-22       Impact factor: 6.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.